Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.30 - $30.03
Previous CloseN/A
Volume37.78K
Average Volume (3M)314.93K
Market Cap
$880.61M
Enterprise Value$808.31M
Total Cash (Recent Filing)$124.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 08, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding49,004,425
10 Day Avg. Volume338,419
30 Day Avg. Volume314,925
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.75
Forecast
1Y Price Target
$38.00Price Target Upside107.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Enliven Therapeutics News
See All ELVN News
---
Bulls Say, Bears Say
Bulls Say
Financial PositionEnliven has a strong cash position with $313.4 million in cash, cash equivalents, and marketable securities, providing a cash runway into mid-2027.
Market StrategyThe design of ELVN-001 as a follow-on therapy post Novartis' Scemblix, which has been successful, highlights a significant market opportunity.
Product DevelopmentELVN-001 has shown a favorable profile compared to approved TKIs with a major molecular response rate of 44% among late line patients by 24 weeks.
Bears Say
Market CompetitionThe HER2 program is in a competitive space with high development costs, posing potential financial challenges.
Short InterestThe stock has a significant short interest, representing 23.3% of the float, which could indicate investor skepticism.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $13.30 and its highest was $30.03 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $880.61M.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.515 by $0.055.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 49,004,425 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.515. Following the earnings report the stock price went up 2.218%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
---
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (107.65% Upside)
$38.00 (107.65% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 206.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.30%
12-Months-Change
Fundamentals
Return on Equity
-32.04%
Trailing 12-Months
Asset Growth
19.82%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
---
ELVN Stock 12 Month Forecast
Average Price Target
$38.00
▲(107.65% Upside)
Technical Analysis
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
+10.43%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +10.43% per trade.
---